MyFinsight
Home
Blog
About
Contact
Download
Download image
Innovative Medicine
$60,401M
(6.03%↑ Y/Y)
Med Tech
$33,792M
(6.07%↑ Y/Y)
Sales to customers
$94,193M
(6.05%↑ Y/Y)
Gross profit
$63,937M
(4.22%↑ Y/Y)
Other (income)
expense, net
$7,209M
(253.58%↑ Y/Y)
Cost of products sold
$30,256M
(10.14%↑ Y/Y)
Interest income
$1,056M
(-20.72%↓ Y/Y)
Earnings before
provision for taxes on...
$32,581M
(95.25%↑ Y/Y)
Selling, marketing and
administrative expenses
$23,676M
(3.53%↑ Y/Y)
Research and development
expense
$14,665M
(-14.90%↓ Y/Y)
Interest expense, net of
portion capitalized
$971M
(28.61%↑ Y/Y)
Restructuring
$228M
(-2.56%↓ Y/Y)
In-process research and
development impairments
$81M
(-61.61%↓ Y/Y)
Net earnings from
continuing operations
$26,804M
(90.56%↑ Y/Y)
Effective rate
$5,777M
(120.41%↑ Y/Y)
Net earnings
$26,804M
(90.56%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
JNJ_BIG_BIG copy-svg
JOHNSON & JOHNSON (JNJ)
JNJ_BIG_BIG copy-svg
JOHNSON & JOHNSON (JNJ)